Case | HBS Case Collection | March 2014

Novartis' Sandoz: Between Generics and Pharma

by Krishna Palepu and Carin-Isabel Knoop

Abstract

Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?

Keywords: Global Strategy and Leadership; Managing Within a Multi-Business Organization; Generic Pharmaceuticals; Global Strategy;

Citation:

Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.